RxDoctor Payments Data

Luis Artavia, MD

Family Medicine · Burbank, CANPI 1407885577

Payments from drug & device makers

$6,650in general payments, 2019–2025

Across 308 payments — averaging $21.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$815
  • Boehringer Ingelheim$722
  • AbbVie$663
  • AstraZeneca$588
  • Amgen$547
  • Lilly USA, LLC$358
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,650100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,650 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$15,407
Medicare patients
55
Services billed
250

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban103$76,735
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$70,534
JardianceEmpagliflozin71$60,854
OzempicSemaglutide64$60,428
MounjaroTirzepatide39$44,347
FarxigaDapagliflozin Propanediol43$39,383
XareltoRivaroxaban43$31,278
JanuviaSitagliptin Phosphate33$29,438
EntrestoSacubitril/Valsartan27$26,375
RybelsusSemaglutide16$26,110
JanumetSitagliptin Phos/Metformin Hcl12$14,089
Combivent RespimatIpratropium/Albuterol Sulfate16$12,510
MyrbetriqMirabegron15$12,435
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr13$6,941
Atorvastatin Calcium614$6,139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$204$86,53880 claims
GSKTrelegy Ellipta, Anoro Ellipta$815$77,47467 claims
PfizerEliquis$149$76,735103 claims
Boehringer IngelheimJardiance, Combivent Respimat$722$73,36487 claims
Lilly USA, LLCMounjaro$358$44,34739 claims
MerckJanuvia, Janumet$89$43,52745 claims
AstraZenecaFarxiga, Symbicort$588$42,70556 claims
Johnson & JohnsonXarelto$178$31,27843 claims
NovartisEntresto$213$26,37527 claims
Astellas Pharma US IncMyrbetriq$71$12,43515 claims
Hikma Pharmaceuticals USAEpinephrine$14$1,87411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Burbank

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →